IngredientsBitter principals (more commonly spelled bitter principles in the botanical and pharmacognostic literature) is a collective term for a structurally diverse group of naturally occurring phytochemicals that share a defining property: an intensely bitter taste detectable at very low concentrations. The term does not designate a single chemical entity but rather a functional category encompassing several major chemical classes found across the plant kingdom. The bitter compounds in foods and medicinal plants mainly include alkaloids, polyphenols, terpenoids, and amino acid derivatives.
Studies on the mechanisms of chemoprotection have focused on the biological activity of plant-based phenols and polyphenols, flavonoids, isoflavones, terpenes, and glucosinolates. However, most, if not all, of these bioactive compounds are bitter, acrid, or astringent.
The principal chemical classes that constitute bitter principles, and representative source plants, are:
Bitter principles are commercially prepared and historically used in several forms:
The use of bitter-tasting plants as digestive remedies represents one of the most ancient and cross-culturally consistent patterns in herbal medicine.
The use of bitter herbs dates back to Ancient Egypt, where papyrus scrolls document the medicinal use of bitter plants like wormwood and gentian. The Ebers Papyrus (c. 1550 BCE), one of the oldest medical texts, describes the use of bitter herbs for digestive ailments, including myrrh, gentian, and aloe. Hippocrates (c. 460β370 BCE) recommended "amara" (bitters) for digestion, believing bitter flavors stimulated bile production. Dioscorides in De Materia Medica (c. 50β70 CE) lists bitter herbs such as gentian and wormwood for stomach health.
In traditional Chinese medicine, a medical system dating more than 5,000 years, bitter plants such as gentian (known as 'lung tan' in Chinese) were used for medicinal purposes. According to Emil Bretschneider, physician to the Russian Legation in Beijing in the late 19th century, the use of gentian was first recorded around the time of Christ in the Shen Nung Pen-ts'ao king, one of China's oldest and most revered works on herbal medicine. The root and leaves of Gentiana scabra and Gentiana macrophylla have been used in Chinese herbalism for over 2,000 years as an excellent tonic for the digestive system, acting on the stomach, liver, and gallbladder. Chinese healers recognized that bitter tastes could "clear heat," reduce inflammation, and support liver function β principles aligned remarkably well with contemporary scientific understanding.
The use of bitters dates back thousands of years and is a fundamental consideration in the Ayurvedic diet, in which food is balanced between bitter, sour, and sweet in order to maintain balance in various bodily systems. In Ayurveda, bitter herbs are considered balancing for certain doshas, or constitutions. In traditional Chinese and Ayurvedic medicine, bitters were frequently prescribed to address issues such as sluggish digestion, skin conditions, and mild liver dysfunction.
Traditional European medicine can trace the use of herbal bitters back to ancient Greece, approximately 4,000 years ago. Historically, these substances played a significant role in traditional medicine across cultures; for centuries, practitioners in Europe, Asia, and Africa incorporated bitter herbs β like gentian, dandelion, and wormwood β into remedies aimed at stimulating digestion and appetite. The roots of Gentiana lutea were utilized in preparing various beverages and herbal remedies, serving as a traditional remedy for gastrointestinal ailments, especially appetite loss and flatulence; extracts made from the plant were used to stimulate gastric acid secretion and for treating gastritis, jaundice, and other gastrointestinal and hepatic diseases.
The 19th century marked a golden age of herbal bitters in America. European colonists brought their knowledge of herbal bitters to the New World, where they encountered Native American traditions that also valued bitter plants; indigenous peoples had long used plants like wild cherry bark, yellow dock, and goldenseal for digestive and medicinal purposes.
Herbalists often crafted tonics or tinctures combining multiple bitter herbs to amplify these effects, creating blends tailored to individual needs. The theory behind their use was that the bitter taste signals the body to increase saliva, gastric acid, and bile production, thereby supporting optimal digestive function. In addition to digestive benefits, bitter principles were believed to help cleanse the body, tone the liver, and strengthen overall vitality. This tradition is reflected in the formulation of aperitifs and digestive bitters commonly consumed before or after meals in many parts of the world.
The molecular basis of bitter-principle activity has been substantially clarified by the characterization of the TAS2R (Type 2 taste receptor) family of G protein-coupled receptors. By binding to specific sites of bitter receptors (26 hTAS2Rs), bitter compounds activate the downstream signaling pathways mediated by G protein, which convert chemical signals into electrical signals ultimately transmitted to the brain to produce the bitter perception. Bitter taste, sensed by 25 subtypes of the TAS2R family of GPCRs, is an aversive stimulus historically considered a toxicity detector.
Key bitter compounds from major medicinal herbs bind to multiple TAS2R subtypes simultaneously. Amarogentin from gentian stimulates seven receptors β TAS2R1, 4, 39, 43, 46, 47, and 50; absinthin from wormwood stimulates four β TAS2R10, 14, 46, and 47.
A major advance in understanding bitter principles has been the discovery of functional TAS2R expression throughout the gastrointestinal tract, well beyond oral taste buds. Taste 2 receptors (TAS2Rs in humans) detect bitterness; these receptors are also expressed in extraoral sites, including the gastrointestinal mucosa. These bitter taste receptors are expressed in functionally distinct types of gastrointestinal mucosal cells, including enteroendocrine cells, which, upon stimulation, increase intracellular CaΒ²βΊ and release signalling molecules that regulate gut chemosensory processes critical for digestion and absorption of nutrients, for neutralization and expulsion of harmful substances, and for metabolic regulation.
TAS2Rs are also found in Paneth and goblet cells, which release antimicrobial peptides and glycoproteins, and in tuft cells, which trigger type 2 immune responses against parasites, thus providing a direct line of defence against pathogens.
One of the most pharmacologically significant consequences of gut TAS2R activation is the stimulation of enteroendocrine hormone release. TAS2Rs expressed on enteroendocrine cells are involved in regulating the secretion of both orexigenic (ghrelin) and anorexigenic peptides (GLP-1, PYY, CCK) that affect hunger scores and food intake in humans and mice. More specifically, TAS2Rs have been demonstrated on enteroendocrine cell lines and affect the secretion of the anorexigenic peptides cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), while gavage of bitter tastants induced CCK-dependent hindbrain activation.
Ageing was found to upregulate TAS2R4, -5, -13, -20 and GLP-1 mRNA in the descending colon. Stimulating TAS2R14 in cell lines induced GLP-1 secretion, while stimulating TAS2R5 modulated GLP-1 and PYY secretion.
Two mechanistic models have been proposed for how oral bitter stimulation enhances digestion. The local-response model holds that bitter tastants act directly on the mucosa of the upper gastrointestinal tract and especially on the bitter receptors to release saliva and gastric juices β a hypothesis supported by studies showing that bitter, sour, sweet, and umami taste receptor cells are present in the stomach, duodenum, jejunum, ileum, and colon. The cephalic-phase model posits that the taste is interpreted in the brain and causes stimuli to be forwarded through the vagus nerve to both the salivary gland and the stomach. The taste is interpreted as bitter and causes stimuli to be forwarded through the vagus nerve to both the salivary gland and the stomach, stimulating the digestive processes and enhancing the appetite.
Research has proposed that the vascular response represents a sympathetic reflex distinct from direct receptor stimulation. The vascular response is a sympathetic reflex, evident after five minutes and dose dependent; thus gentian and wormwood elicit cephalic responses which facilitate rather than stimulate digestive activity when postprandial hyperaemia is inadequate.
Gentiopicroside (GPS), a secoiridoid glycoside found in traditional medicinal plants such as Gentiana scabra Bunge, exhibits diverse pharmacological properties, including anti-inflammatory, antioxidant, neuroprotective, hepatoprotective, antidiabetic, antitumor, and skin disease-modulating effects. GPS modulates key signaling pathways, such as NF-ΞΊB and MAPK, to suppress pro-inflammatory cytokines and oxidative stress; it also activates the Keap1-Nrf2 pathway to enhance cellular antioxidant defenses and exhibits direct free radical scavenging capabilities.
Gentiana extracts target NF-ΞΊB and MAPK pathways to suppress inflammation and oxidative liver injury via Nrf2 activation, while inducing tumor cell apoptosis (Bax/Bcl-2) and S/G2-M phase arrest to inhibit lung/liver cancer proliferation.
Regarding gentiopicroside's anti-inflammatory GI effects: gentiopicroside treatment can have anti-inflammatory effects in experimental acute colitis by reducing the expression levels of TNF-Ξ±, IL-1Ξ², IL-6, iNOS, and COX-2, suggesting its potential therapeutic application in the treatment of colitis.
The gastroprotective hierarchy among secoiridoids has also been characterized: another study reported that secoiridoidal glycosides isolated from different Gentiana species have several important activities, and amarogentin and amaroswerin have the strongest gastroprotective effects among the other secoiridoids.
Cynarin, a compound found in artichoke (Cynara scolymus), has documented choleretic (bile-stimulating) effects in controlled extract studies, according to the European Medicines Agency's monograph on artichoke leaf (EMA/HMPC/150957/2014). The choleretic action of the plant has been well documented in a controlled trial involving a small sample of healthy volunteers; after the administration of 1.92 grams of standardized artichoke extract directly into the duodenum, liver bile flow increased significantly.
The potent effects of bitter substances to stimulate glucoregulatory hormones, particularly GLP-1, and slow gastric emptying β a major determinant of postprandial blood glucose β have provided a rationale for investigating these compounds' capacity to reduce postprandial blood glucose levels; this is of major clinical relevance since in type 2 diabetes, postprandial glycaemic excursions are a dominant determinant of average glycaemic control. A consistent effect of bitter compounds to lower postprandial blood glucose has been reported across multiple studies.
This is the area of most developed human clinical evidence for bitter principles. One study aimed to assess the efficacy of artichoke leaf extract (ALE) in the treatment of functional dyspepsia (FD). In a double-blind RCT, 247 patients with functional dyspepsia were recruited and treated with either a commercial ALE preparation (2 Γ 320 mg plant extract t.d.s.) or a placebo. Data from 244 patients were suitable for inclusion in the intention-to-treat analysis. The overall symptom improvement over 6 weeks of treatment was significantly greater with ALE than with placebo. The ALE preparation was significantly better than placebo in alleviating symptoms and improving disease-specific quality of life in patients with functional dyspepsia.
A separate study examined a combination preparation: artichoke extract administration improved overall symptoms and quality of life at 6 weeks compared to placebo in one double-blind RCT of 247 patients with functional dyspepsia; similar advantages were shown in a mixed artichoke and ginger supplement.
Specifically regarding the ginger-artichoke combination RCT: a prospective, multicentre, double-blind, randomized, placebo-controlled, parallel-group comparison of the combined ginger and artichoke leaf extract supplement and placebo over four weeks was performed; two capsules per day were supplied to 126 FD patients (supplementation/placebo: 65/61). After 14 days of treatment, only the supplementation group showed a significant amelioration (MCA score: +1.195 units, P = 0.017; placebo: +0.347 units, P = 0.513).
An earlier uncontrolled clinical trial with artichoke extract: after the administration of 1.92 grams of standardized artichoke extract directly into the duodenum, liver bile flow increased significantly. This choleretic effect has led to popular use in Europe for mild indigestion, particularly after a meal high in fat. In an uncontrolled clinical trial with 553 people suffering from non-specific digestive disorders (including indigestion), 320β640 mg of a standardized artichoke extract taken three times per day was found to reduce nausea, abdominal pain, constipation, and flatulence in over 70% of study participants.
For gentian specifically, an important multicenter study was noted: a multicentre, uncontrolled study of gentian capsules involving 205 patients found that patients taking on average about five capsules per day, each containing 120 mg of a 5:1 dry extract of gentian root, achieved rapid and dramatic relief of symptoms including constipation, flatulence, appetite loss, vomiting, heartburn, abdominal pain, and nausea. However, this was an uncontrolled design and must be interpreted with caution.
Evidence strength: The overall body of clinical evidence remains limited and often consists of small-scale or preliminary studies. The artichoke leaf extract RCTs are the strongest individual clinical data points. Gentian and wormwood as isolated interventions lack well-powered RCT-level evidence in humans.
TAS2Rs and taste signalling elements were expressed in smooth muscle tissue along the mouse gut and in human gastric smooth muscle cells. Bitter tastants induced concentration- and region-dependent contractility changes in mouse intestinal muscle strips. In healthy volunteers, intra-gastric administration of bitter compound DB showed impaired fundic relaxation in response to nutrient infusion and a decreased nutrient volume tolerance and increased satiation during an oral nutrient challenge test.
These findings suggest a potential role for intestinal TAS2Rs as therapeutic targets to alter gastrointestinal motility and hence to interfere with hunger signalling.
Evidence strength: Preliminary. Direct human evidence for bitter herbs (as opposed to isolated bitter compounds administered intragastrically) on motility and satiety is limited. The mechanism is well-characterized at the receptor level but its clinical translation to herbal products is not yet well established in controlled human trials.
Cardiovascular diseases are the chief causes of death in the UK and are associated with high circulating levels of total cholesterol. Artichoke leaf extracts have been reported to reduce plasma lipid levels, including total cholesterol, although high quality data is lacking. One trial assessed the effect of ALE on plasma lipid levels in otherwise healthy hypercholesterolemic adults; 131 adults were screened for total plasma cholesterol in the range 6.0β8.0 mmol/L, with 75 suitable volunteers randomised. Volunteers consumed 1,280 mg of standardised ALE or matched placebo daily for 12 weeks. Plasma total cholesterol decreased in the treatment group by an average of 4.2% and increased in the control group by an average of 1.9%, the difference between groups being statistically significant.
Evidence strength: Modest. The one well-controlled RCT for cholesterol reduction used standardized artichoke extract at a defined dose and showed a statistically significant but clinically modest effect. Replication in larger trials is needed.
The effects of bitter compounds on GLP-1 secretion have been studied extensively. A number of bitter compounds have been shown to stimulate GLP-1 in both cell-line and animal studies. A number of bitter substances have potent effects to lower postprandial blood glucose, although evidence to support the involvement of specific receptor subtypes or the role of hormones, particularly GLP-1, is limited.
For bitter melon: recent studies indicate that cucurbitanoid compounds are the active principals of bitter melon which possess hypoglycaemic properties; so far, only a few non-randomized clinical studies have investigated the anti-diabetic effects of bitter melon in man.
Evidence strength: Preclinical evidence (cell and animal studies) is substantial. Human clinical translation is preliminary and inconsistent, particularly for bitter herbs as whole extracts versus isolated bitter compounds. The Momordica charantia literature is specifically limited by poor trial design.
Studies have demonstrated that bitter foods have biological activities such as preventing hyperlipidemia, hypertension, hyperglycemia, anti-inflammatory, antitumor, antibacterial, and antioxidant effects, and exhibit neuroprotective activities. Bitter foods can also inhibit the production of inflammatory factors, reduce inflammatory responses, clear free radicals in the human body, and reduce oxidative stress responses, thus helping to prevent the occurrence of many chronic diseases.
Evidence strength: Largely preclinical (in vitro and animal models). Robust human clinical trials specifically targeting bitter principles as anti-inflammatory agents are lacking as of the current literature.
The hepatoprotective effects of gentiopicroside include mitigating chemical- and alcohol-induced liver damage by regulating lipid metabolism and reducing fibrosis. The hepatoprotective activities of secoiridoids are related to sweroside, swertiamarin, and gentiopicrin, constituents of gentian root.
Evidence strength: Primarily preclinical (in vitro and rodent model). Direct human hepatoprotection trials for bitter principles are absent from the reviewed literature.
Bitter taste receptors (TAS2Rs) serve as warning sensors in the lingual system against the ingestion of potentially poisonous food; human jejunal crypts, especially those from individuals with obesity, responded to bitter agonists by inducing the release of antimicrobial peptides (Ξ±-defensin 5 and REG3A) and by regulating the expression of other innate immune factors (mucins, chemokines). TAS2Rs in the intestine constitute a promising target for treating diseases that involve disturbances in the innate immune system and body weight control.
Evidence strength: Emerging and preclinical/ex vivo. This represents a novel frontier in bitter-principle research; clinical translation in human trials has not yet been established.
In neurodegenerative diseases like Alzheimer's and Parkinson's, gentiopicroside reduces amyloid-Ξ² accumulation and dopaminergic neuron loss, respectively.
Evidence strength: Preclinical only. These are animal and cell-culture findings. No human clinical trial data in neurodegenerative disease contexts was identified for bitter principles as a class or for gentiopicroside specifically.
The following dosages appear in the peer-reviewed studies cited above:
No universally standardized dosing range has been established across all bitter principles as a class. Dosages vary substantially by plant species, extract standardization, and therapeutic indication.
Drinking wormwood as a tea is generally safe, but its essential oil and the liqueur absinthe, made from an alcohol extract of the plant, can be dangerous in large amounts because of a substance called thujone. Thujone can be harmful to the brain and cause hallucinations and long-term mental health problems if consumed in large doses. It is therefore important to use wormwood products that do not contain thujone. The compound thujone prompted the 19th-century absinthe ban and is now regulated by the European Union at a maximum of 35 mg/kg in spirits (EU Regulation 110/2008).
Bitter principles should not be used with active ulcers or gastritis; bitters increase stomach acid and can worsen mucosal irritation in people with peptic ulcer disease or active inflammation. In one RCT of artichoke and ginger extract, patients with active Helicobacter pylori infection or with gastric or duodenal ulcer were excluded from the study.
The practice of using wormwood to treat indigestion is mostly based on traditional knowledge rather than clinical studies. This is an important caveat when comparing the evidence base for wormwood versus artichoke leaf extract.
When elevated doses are given, no major toxic effects have been identified so far in any of the mentioned in vivo studies regarding the Gentiana genus. Amarogentin at a dose of 1,000 mg/kg did not produce any signs of toxicity for up to 14 days in C57BL/6 mice. Gentiana macrophylla root extract caused no mortality and abnormal performance at the dose of 500 mg/kg in Kunming mice after 48 hours. However, these are animal studies and cannot be directly extrapolated to human safety.
Assessment of herb-drug interactions should take into account the clinical relevance, including the nature of the evidence, the plausibility of the mechanism, and the potential impact on patient safety. Not all reported or theoretical interactions have the same clinical significance. Herb-drug interactions should be interpreted in the context of the patient's medication profile, clinical condition, and risk factors.
Because bitter principles stimulate gastric acid secretion and bile flow, they have a theoretical potential to alter the absorption of concomitantly administered drugs whose bioavailability is sensitive to gastric pH or to bile emulsification.
The use of herbal medicinal products during pregnancy and the postnatal period should be discouraged until robust evidence of safety is available. Despite the common perception that herbal medicines are safe, herbal medicines may have potent pharmacological actions and have, in fact, been used for centuries as emmenagogues to promote abortion. Several bitter herbs, including wormwood (Artemisia absinthium), are specifically classified as contraindicated in pregnancy within pharmacopoeia-referenced resources.
Given the documented choleretic and cholagogue actions of multiple bitter principles β particularly artichoke and gentian β these preparations are contraindicated in cases of bile duct obstruction and should be used with caution in gallstone disease, consistent with the EMA's guidance on artichoke leaf extract.
While there is considerable anecdotal and historical support for the use of bitters, scientific validation remains limited but suggestive. The most robust human clinical data pertains to standardized artichoke leaf extract for functional dyspepsia and mild hypercholesterolaemia. For most other bitter herbs and most other indications, the evidence base consists of preclinical studies, small uncontrolled trials, and traditional use documentation β and should be characterized as preliminary.
Health conditions that Bitter principals may help support.
Body systems that Bitter principals may help support.
Go back